These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
526 related articles for article (PubMed ID: 23953622)
21. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Mitchell JA; Warner TD Nat Rev Drug Discov; 2006 Jan; 5(1):75-86. PubMed ID: 16485347 [TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacology of selective COX-2 inhibitors. Capone ML; Tacconelli S; Sciulli MG; Patrignani P Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704 [TBL] [Abstract][Full Text] [Related]
23. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Hermann M; Ruschitzka F Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448 [TBL] [Abstract][Full Text] [Related]
24. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Vuolteenaho K; Moilanen T; Moilanen E Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):10-4. PubMed ID: 17973900 [TBL] [Abstract][Full Text] [Related]
25. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Laine L Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071 [TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Jones R; Rubin G; Berenbaum F; Scheiman J Am J Med; 2008 Jun; 121(6):464-74. PubMed ID: 18501223 [TBL] [Abstract][Full Text] [Related]
27. COX-2 inhibitors: pharmacological data and adverse effects. Mattia C; Coluzzi F Minerva Anestesiol; 2005; 71(7-8):461-70. PubMed ID: 16012420 [TBL] [Abstract][Full Text] [Related]
28. [Management of Adverse Effects Associated with Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitor]. Masuda R Masui; 2016 Aug; 65(7):709-717. PubMed ID: 30358302 [TBL] [Abstract][Full Text] [Related]
30. [Is there a future for COX-2 inhibitors?]. Yodfat Y Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272 [TBL] [Abstract][Full Text] [Related]
31. Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib. Urdaneta A; Siso A; Urdaneta B; Cardenas R; Quintero L; Avila R; Suarez-Roca H Brain Res Bull; 2009 Aug; 80(1-2):56-61. PubMed ID: 19463915 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Borer JS; Simon LS Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077 [TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. St Germaine CG; Bogaty P; Boyer L; Hanley J; Engert JC; Brophy JM Am J Cardiol; 2010 Jun; 105(12):1740-5. PubMed ID: 20538124 [TBL] [Abstract][Full Text] [Related]
37. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Hur C; Chan AT; Tramontano AC; Gazelle GS Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709 [TBL] [Abstract][Full Text] [Related]